Understand
Understand the terms of immunogenicity & antigenicity
pharma
Immunogenicity MasterClass - EU edition
22-23 March, 2027
22-23 March, 2027Virtual
MasterClass in Pharma
An important topic for complex therapeutics – Biologics, Biopharmaceuticals, Biosimilars
22-23 March, 2027, Virtual
Time Zone : UTC/GMT+1 /CET
Key learnings
Gain Insight
Gain insight into different analytical tools
Discuss
Discuss distinct approaches to control ADAs
Find Solutions
Find solutions for immunogenicity challenges
Predict
Predict animal data to overcome clinic hurdles
Different Drugs
Different drugs - different danger for SAE
Trusted by over 17,000 delegates across leading companies
Overview
Overview
Main Benefits or Value Propositions of Attending This Event:
Learn about cutting-edge advancements in immunogenicity testing, including computational models, and regulatory strategies.
Gain actionable insights to enhance testing accuracy and successful regulatory submissions.
Access to advanced resources and case studies
Stay updated on trends driving the future of precision medicine and biologic safety.
How Attendees Knowledge or Skills Will Be Improved:
Gain a deeper understanding of modern tools and techniques for immunogenic responses.
Enhance skills in integrating computational models and latest techniques in immunogenicity testing.
Develop expertise in navigating regulatory guidelines to ensure compliance and minimize risks.
Learn to apply advanced in vitro testing methodologies in research, generics, discovery and clinical workflows.
What Sets This Event Apart:
Focus on the intersection of science and compliance, providing a holistic view of immunogenicity testing advancements.
Offers practical, future-ready strategies tailored to address industry challenges.
Emphasis on actionable outcomes through interactive sessions and case studies
Designed for professionals aiming to stay ahead of trends in biologic safety
#masterclass #pharmaonlinemasterclass #glceurope #globalleadingconferences #immunogenicity
Meet the expert
Trainer
Dr. Markus Fido
Founder, & Managing Director at MFI Bio-Consulting
Markus has more than 25 years of experience in pharmaceutical industry, with focusin vaccines, recombinant proteins, and immune therapeutics. He has profoundexpertise in regulatory aspects such as third-party audits, authority inspections andGMP guidelines.
He has a management consulting education and holds a doctorate degree in immunology/biochemistry from the Technical University of Graz, Austria. Markus started his carrier at a Novartis “Spin off” in Vienna in 2006, later on he has acquired the oncology division from Novartis and founded 2 Biotech companies, VelaLabs & Meridian Biopharmaceutics.
Besides serving as a CEO and formal Managing Director, Markus has also taken responsibilities as a Head of Regulatory Affairs within the Quality Operations team. Markus was previously Head Quality Control at Igeneon / Aphton Biopharma where he was responsible for all QC aspects of pre-clinical and clinical projects such as stability studies, specifications, method validation, and product release. Before he was Group Leader of Immunology and Product Development at Biomin GmbH, Head Biochemical Control at Baxter AG and Head Quality Operations at Octapharma AG.
Reasons to attend a masterclass
Practical knowledge
Venture into undiscovered territories and gain inspiration through collaboration
Interactivity
Boost your professional skills by directly engaging with domain experts
World-class trainers
Gain value and learn from the best instructors
Networking
Build a top-notch community and advance your career
Recommendation
WHO SHOULD ATTEND
• Clinical trial manager
• Product development specialists
• CSO/COOs in Biotech industry
• Analytical development Heads
• Members of QC departments
• Members for product analytics
• Clinicians & Principal investigators
• Personal from CROs
• R&D scientists for complex drugs
• Members of agencies & authorities
14+
Years of experience
600+
Events organized
4,000+
Speakers
25,000+
Attendees
Take the next step